Abstract:Objective: To summarize the pharmacology of the calcitonin peptide family of receptors and explore their relationship to migraine and current migraine therapies. Background: Therapeutics that dampen calcitonin gene-related peptide (CGRP) signaling are now in clinical use to prevent or treat migraine. However, CGRP belongs to a broader peptide family, including the peptides amylin and adrenomedullin. Receptors for this family are complex, displaying overlapping pharmacologic profiles. Despite the focus on CGRP and the CGRP receptor in migraine research, recent evidence implicates related peptides and receptors in migraine. Methods: This narrative review summarizes literature encompassing the current pharmacologic understanding of the calcitonin peptide family, and the evidence that links specific members of this family to migraine and migraine-like behaviors. Results: Recent work links amylin and adrenomedullin to migraine-like behavior in rodent models and migraine-like attacks in individuals with migraine. We collate novel information that suggests females may be more sensitive to amylin and CGRP in the context of migraine-like behaviors. We report that drugs designed to antagonize the canonical CGRP receptor also antagonize a second CGRP-responsive receptor and speculate as to whether this influences therapeutic efficacy. We also discuss the specificity of current drugs with regards to CGRP isoforms and how this may influence therapeutic profiles. Lastly, we emphasize that receptors related to, but distinct from, the canonical CGRP receptor may represent underappreciated and novel drug targets. Conclusion: Multiple peptides within the calcitonin family have been linked to migraine. The current focus on CGRP and its canonical receptor may be obscuring pathways to further therapeutics. Drug discovery schemes that take a wider view of the receptor family may lead to the development of new anti-migraine drugs with favorable clinical profiles. We also propose that understanding these related peptides and receptors may improve our interpretation regarding the mechanism of action of current drugs.

From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment

Pituitary cyclase‐activating polypeptide targeted treatments for the treatment of primary headache disorders

Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine

The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?

Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

Shared and independent roles of CGRP and PACAP in migraine pathophysiology

Potential benefits and possible risks of CGRP-targeted multitherapy in migraine

Migraine Treatment: Towards New Pharmacological Targets

Migraine therapeutics differentially modulate the CGRP pathway

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond

Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention

VPAC1 and VPAC2 receptors mediate tactile hindpaw hypersensitivity and carotid artery dilatation induced by PACAP38 in a migraine relevant mouse model

PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine

CGRP as the target of new migraine therapies — successful translation from bench to clinic

Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model

CGRP, Amylin, Immunology, and Headache Medicine

Potential treatment targets for migraine: emerging options and future prospects

Novel Therapeutic Targets for Migraine

The role of anti-CGRP antibodies in the pathophysiology of primary headaches

Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class

Developments in targeting calcitonin gene-related peptide